Predicting 6-Month Unfavorable Outcome of Acute Ischemic Stroke Using Machine Learning

Xiang Li1,2*, XiDing Pan3†, ChunLian Jiang4†, MingRu Wu1, YuKai Liu5*, FuSang Wang1,2, XiaoHan Zheng1,2, Jie Yang6, Chao Sun1,2, YuBing Zhu3, JunShan Zhou5, ShiHao Wang7, Zheng Zhao3* and JianJun Zou2*

1 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China, 2 Department of Clinical Pharmacology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 3 Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 4 Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 5 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 6 Department of Neurology, the First Affiliated Hospital of Chengdu Medical College, Chengdu, China, 7 School of Public Health, Bengbu Medical College, Bengbu, China

Background and Purpose: Accurate prediction of functional outcome after stroke would provide evidence for reasonable post-stroke management. This study aimed to develop a machine learning-based prediction model for 6-month unfavorable functional outcome in Chinese acute ischemic stroke (AIS) patient.

Methods: We collected AIS patients at National Advanced Stroke Center of Nanjing First Hospital (China) between September 2016 and March 2019. The unfavorable outcome was defined as modified Rankin Scale score (mRS) 3–6 at 6-month. We developed five machine-learning models (logistic regression, support vector machine, random forest classifier, extreme gradient boosting, and fully-connected deep neural network) and assessed the discriminative performance by the area under the receiver-operating characteristic curve. We also compared them to the Houston Intra-arterial Recanalization Therapy (HIAT) score, the Totaled Health Risks in Vascular Events (THRIVE) score, and the NADE nomogram.

Results: A total of 1,735 patients were included into this study, and 541 (31.2%) of them had unfavorable outcomes. Incorporating age, National Institutes of Health Stroke Scale score at admission, premorbid mRS, fasting blood glucose, and creatinine, there were similar predictive performance between our machine-learning models, while they are significantly better than HIAT score, THRIVE score, and NADE nomogram.

Conclusions: Compared with the HIAT score, the THRIVE score, and the NADE nomogram, the RFC model can improve the prediction of 6-month outcome in Chinese AIS patients.

Keywords: cerebral ischemia, machine learning, prediction, unfavorable outcome, stroke
INTRODUCTION

Globally, stroke is a leading cause of mortality and disability (1). In developing countries, the prevalence of stroke is increasing as the population ages. Patients who survive stroke have an increased economic burden due to post-stroke care (2). Therefore, accurate prediction of functional outcome after stroke would provide evidence for reasonable post-stroke management and thus improve the allocation of health care resources.

The prognostic prediction requires the processing of patients' clinical data, such as demographic information, clinical features, and laboratory tests results. Then, the model is developed to predict prognosis based on existing data. Several prognostic models have been developed to predict the clinical outcome after stroke, such as Houston Intra-arterial Recanalization Therapy (HIAT) score, Totaled Health Risks in Vascular Events (THRIVE) score and NADE nomogram (3–5). They are generally based on regression model with the assumption of a linear relationship between variables and the outcomes. The THRIVE score and HIAT score were developed based on Whites or Blacks, not Asians. Compared with White patients, the average age of Asian patients was younger (6, 7). In addition, several studies have observed worse survival in Whites with stroke compared to other race (8, 9). Importantly, the long-term outcomes of stroke were significantly different by race (7). Thus, it is difficult for these models to achieve accurate predictive performances on the Chinese population.

Machine-learning (ML) approaches have been widely used in medical fields (10). Recently, it has shown effective capability in disease prediction, especially in the analysis of large datasets with a multitude of variables (11–13). ML uses computer algorithms to build a model from labeled data and to make data-driven predictions. It enables the computer to process complex non-linear relationships between variables and outcomes, which may be hard to be detected by conventional regression models (14). Such advantages increase the accuracy of prediction model. ML includes multiple algorithms, such as logistic regression (LR), random forest classifier (RFC), support vector machine (SVM), fully-connected deep neural network (DNN), and extreme gradient boosting (XGBoost). The optimal selection of algorithm should be in accordance with the characteristics of the dataset. Meanwhile, the popularity of electronic patient record (EPR) systems and wide availability of structured patient data make sophisticated computer algorithms implemented at the bedside a reality.

In this study, we aim to develop the models using ML method to predict 6-month unfavorable outcomes in Chinese stroke patients, and then compare the performance of ML-based methods with existing clinical prediction scores.

METHODS

Study Population and Clinical Baseline Characteristic

We retrospectively conducted an analysis using a cohort of acute ischemic stroke (AIS) patients who were admitted within 7 days of the onset of symptoms. The cohort included 3,231 consecutive AIS patients admitted at National Advanced Stroke Center of Nanjing First Hospital (China) between September 2016 and March 2019. The exclusion criteria were patients with missing data on pretreatment variables or long-term clinical outcome, signs of intracranial hemorrhage on baseline brain computed tomography scan, age < 18 years. We discarded all variables with 25% missing values or more for further analysis.

All clinical, anamnestic, and demographic characteristics were recorded at the time of admission, including the following data: age, sex, body mass index, National Institute of Health stroke scale (NIHSS) at admission, premorbid modified Rankin Scale (mRS), interval from onset to hospital within 4.5 h, systolic blood pressure, diastolic blood pressure, platelet count, urea nitrogen, creatinine, fasting blood glucose (FBG), and medical history such as hypertension, previous cerebral infarction, and so on. NIHSS at admission and premorbid mRS were presented as continuous variables in all models to increase model efficiency, and the ordinal scores were assumed to be linear. Unfavorable outcome was defined as mRS 3–6, 6 months after stroke. During face-to-face or via telephone follow-up with the patients using structured interview, their relatives or their general practitioners, certified neurologists, evaluated the baseline NIHSS and mRS scores.

Statistical Analysis

The AIS patients were randomly stratified (8:2) into the training set for developing models, and the testing was set for evaluating the models’ performance, which meant that the sampling was in proportion to the original dataset. We initially compared the clinical characteristics of patients with 6-month favorable and unfavorable outcomes in the training set. Continuous variables were reported as median value and interquartile range, and the various groups were explored for differences using the Mann–Whitney U-test. Categorical variables were instead expressed as number of events and percentage, dividing the number of events by the total number excluding missing and unknown cases. To compare categorical variables, Fisher’s exact test or the χ² test were used. To identify which variables were independently associated with poor outcome, all potential variables with \( p < 0.10 \) in the univariable analysis or thought to be independent predictors of ischemic stroke were entered into a multivariable LR with a backward stepwise. Variables with \( p < 0.05 \) were considered statistically significant, and all p were two-sided.

Finally, our models were developed based on ML, including age, premorbid mRS, NIHSS at admission, creatinine, and FBG. All statistical analyses were performed using SPSS version 22.0 (IBM Corporation, Armonk, NY, USA) and Stata version 13.0 (StataCorp, College Station, TX, USA).

Model Development

According to Wolpert’s "No Free Lunch Theorem," no one technique will be most accurate in every case, and so comparisons of techniques in different research areas and datasets may yield different results (15). Therefore, we used 5 ML algorithms: LR, SVM, RFC, XGBoost, and DNN because they are widely and successfully used for clinical data (16–20).

As a standard way of estimating the performance of the model, the k-fold cross-validation method is more reliable than simply
holding out the validation set by giving the variance of the performance and has been used in various reports (16–19). The 5-fold cross-validation was used for the model derivation and internal evaluation by dividing the training set into five mutually exclusive parts, four of which were used as training data to generate the model and one for evaluation as inner validation data; this process was repeated five times to generate five different but overlapping training data and five unique validation data. Due to the long training time and high resource consumption of DNN, we used a random partition of 10% data as a validation set instead of 5-fold cross-validation to optimize the model. In the training step, we optimized model hyperparameters with a grid search algorithm. During the searching process, we set the area under the curve (AUC) of receiver operating characteristic (ROC) as the score.

**Model Evaluation**

After the models were derived, the sensitivity, specificity, accuracy, and AUC were calculated for the testing data. The performances of different models were compared by ROC analysis and Delong test.

For evaluating the superiority of prediction capability for the ML models, we calculated THRIVE score, HIAT score, and NADE nomogram on the same patient group. Although there were some other scores, they were not included because the database lacked information for the calculation (21, 22). In addition, we also developed 2 ML models (LR and RFC models) using 21 variables with \( p < 0.10 \) in a univariable analysis as a reference. After derivation of the models, we calculated the contribution of each variable: the absolute value of the standardized regression coefficient for LR and information gain (which was estimated by the decrease in impurity) for RFC. The five ML models were developed and validated with open-source packages in Python software (version 3.7): Scikit-learn, keras, and XGBoost.

**RESULTS**

**Patient Characteristics**

A total of 3,379 patients were registered to the cohort during the study period. After excluding 1,213 patients with unavailable 6-month mRS scores, 200 patients with unavailable NIHSS at admission, 108 patients with unavailable FBG, and 123 patients with missing other laboratory tests or clinical data, 1,735 patients were finally included (Figure 1). Comparison of demographic variables between the included and excluded patients is shown in **Supplementary Table 1**. The median age of the 1,735 patients was 68 (IQR: 60–78) years, and 67.1% were men. The proportion of patients with unfavorable outcome was 31.2% (541/1,735), and 12.0% (208/1,735) died within the follow-up period (mRS score = 6). The characteristics of the patients were well-balanced between the training (\( n = 1,388, 80\% \)) and testing (\( n = 347, 20\% \)) sets (Supplementary Table 2).

**Feature Selection**

The 21 variables with \( p < 0.10 \) in the univariable analysis or thought to be independent predictors of ischemic stroke (the variables list is shown under Table 1) entered into the LR. After multivariate LR analysis, age, NIHSS at admission, premorbid mRS, FBG, and creatinine remained independent predictors of 6-month unfavorable outcome.

**Model Performance**

The AUC of each model on the training and inner validation sets is provided in **Table 2**. The AUC of each model on the testing set is given as follows (Table 3, Figure 2): LR 0.857 [95% CI, 0.814–0.900], SVM 0.865 [0.823–0.907], RFC 0.862 [0.820–0.904], XGBoost 0.858 [0.815–0.901], and DNN 0.867 [0.827–0.908]. *P*-values for AUC of RFC compared with LR, SVM, XGBoost, and DNN were 0.885, 0.930, 0.898, and 0.848, respectively. Although there was no difference in AUC between the ML models, we chose the RFC model to compare with previously reported models.

The RFC model performed significantly better than the THRIVE score [AUC 0.862 [0.820–0.904] vs. 0.771 [0.721–0.822]; \( p = 0.007 \)], HIAT score [AUC 0.862 [0.820–0.904] vs. 0.686 [0.630–0.743]; \( p < 0.0001 \)], and NADE nomogram [AUC 0.862 [0.820–0.904] vs. 0.813 [0.763–0.862]; \( p = 0.011 \)] (Figure 3). The sensitivity of RFC model is 0.657, while specificity is 0.883.

After we developed LR and RFC model with 21 variables, the performance of ML models did not differ from these models with five variables [0.857 [0.814–0.900] vs. 0.866 [0.825–0.907]; \( p = 0.755 \) and 0.862 [0.820–0.904] vs. 0.874 [0.835–0.912]; \( p = 0.665 \)] (Table 3, Figure 4). Furthermore, we calculated the six most important variables in LR and RFC model using 21 variables. Age, NIHSS at admission, premorbid mRS, FBG, and creatinine also appeared as the most important variables (Table 4).
TABLE 1 | Clinical, demographic and laboratory data of the patients in the training set stratified according to 6-month favorable or unfavorable outcome after acute ischemic stroke.

|                      | Favorable outcome (mRS 0–2) | Unfavorable outcome (mRS 3–6) | P-value |
|----------------------|-----------------------------|-----------------------------|--------|
| Patients, n          | 955                         | 433                         | < 0.0001 **                         |
| Age, years, median (IQR) | 66 (58–74)                    | 77 (68–83)                  |        |
| Sex, n (%)           |                              |                             | < 0.0001*                          |
| Male                 | 682 (71.4)                   | 254 (58.7)                  |        |
| Female               | 273 (28.6)                   | 179 (41.3)                  |        |
| Onset-to-admission delay <4.5 h, n (%) | 236 (24.7)                    | 127 (29.3)                  | 0.070* |
| Medical history, n (%) |                              |                             |        |
| Hypertension         | 650 (68.1)                   | 317 (73.2)                  | 0.053* |
| Diabetes mellitus    | 248 (26.0)                   | 143 (33.0)                  | 0.007* |
| Hyperlipidemia       | 29 (3.0)                     | 6 (1.4)                     | 0.069* |
| Coronary artery disease | 100 (10.5)                  | 77 (17.8)                   | < 0.0001*                         |
| Atrial fibrillation  | 75 (7.9)                     | 95 (21.9)                   | < 0.0001*                         |
| Previous cerebral infarction | 123 (12.9)                 | 102 (23.8)                  | < 0.0001*                         |
| Valvular heart disease | 13 (1.4)                     | 8 (1.8)                     | 0.492  |
| Smoking, n (%)       |                              |                             | < 0.0001*                          |
| Never smoker         | 394 (41.3)                   | 255 (58.9)                  |        |
| Former smoker        | 129 (13.5)                   | 66 (15.2)                   |        |
| Current smoker       | 432 (45.2)                   | 112 (25.9)                  |        |
| Drinking, n (%)      |                              |                             | < 0.0001*                          |
| Never drinker        | 525 (55.0)                   | 307 (70.9)                  |        |
| Former drinker       | 84 (8.8)                     | 47 (10.9)                   |        |
| Current drinker      | 348 (36.2)                   | 79 (18.2)                   |        |
| Baseline data        |                              |                             |        |
| Premorbid mRS, median (IQR) | 0 (0–0)                     | 0 (0–2)                     | < 0.0001 # **                        |
| NIHSS at admission, median (IQR) | 3 (2–5)                     | 10 (5–16)                   | < 0.0001 # **                        |
| BMI, kg/m², median (IQR) | 24.38 (22.38–26.64)         | 24.03 (21.60–26.37)         | 0.046 # *                          |
| Pulse, times/min, median (IQR) | 76 (70–80)                  | 76 (70–84)                  | 0.005 # *                          |
| Systolic BP, mmHg, median (IQR) | 140 (130–160)           | 142 (130–160)               | 0.350#                          |
| Diastolic BP, mmHg, median (IQR) | 84 (80–94)                 | 83 (78–95)                  | 0.533#                          |
| Platelet count, 10⁹/L, median (IQR) | 195 (159–234)            | 186 (150–238)               | 0.159#                          |
| Urea nitrogen, mmol/L, median (IQR) | 5.23 (4.4–6.34)         | 6.12 (4.71–7.75)            | < 0.0001 # **                        |
| Creatinine, µmol/L, median (IQR) | 71 (59–83)                 | 76 (62–97)                  | < 0.0001 # **                        |
| FBG, mmol/L, median (IQR) | 5.08 (4.50–6.21)          | 6.40 (5.05–7.99)            | < 0.0001 # **                        |
| TC, mmol/L, median (IQR) | 4.41 (3.76–5.16)          | 4.41 (3.84–5.18)            | 0.574#                          |
| TG, mmol/L, median (IQR) | 1.31 (0.96–1.88)          | 1.18 (0.84–1.59)            | < 0.0001 # **                        |
| LDL, mmol/L, median (IQR) | 2.71 (2.13–3.31)          | 2.76 (1.96–3.27)            | 0.470#                          |
| HDL, mmol/l, median (IQR) | 1.05 (0.9–1.23)           | 1.08 (0.9–1.26)             | 0.165#                          |
| Endovascular therapy, n (%) | 72 (7.5)                   | 55 (12.7)                   | 0.002*                          |
| IV thrombolysis, n (%) | 208 (21.8)                 | 119 (27.5)                  | 0.020*                          |

mRS, modified Rankin Scale; IQR, interquartile range; NIHSS, National Institute of Health stroke scale; BMI, body mass index; BP, blood pressure; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; IV, intravenous.

#calculated using Mann-Whitney U-test.
*included into the multiple logistic regression models (P < 0.1).

DISCUSSION

To the best of our knowledge, this is the first study that develops prediction models with ML methods for the 6-month clinical outcome of AIS patients. For predicting 6-month unfavorable functional outcome in Chinese AIS patients, our study suggested that the RFC model is more accurate than the HIAT score, the THRIVE score, and the NADE nomogram. End users in clinical practice will be able to perform more accurate evaluation of long-term outcome for AIS patients when our models are fed five easily accessible variables. Thus, it interests clinical physicians because of importance of outcome prediction for patients and their families. Although, there are some criticisms about ML techniques because they are black...
### TABLE 2 | The area under the curve (AUC) of training set and inner validation set.

| Models    | Training set (95% CI) | Inner validation set (95% CI) |
|-----------|-----------------------|------------------------------|
| LR        | 0.867 (0.847–0.888)   | 0.862 (0.812–0.911)          |
| SVM       | 0.874 (0.855–0.894)   | 0.871 (0.840–0.901)          |
| RFC       | 0.897 (0.880–0.915)   | 0.866 (0.831–0.902)          |
| XGBoost   | 0.890 (0.872–0.908)   | 0.867 (0.833–0.901)          |
| DNN       | 0.877 (0.858–0.897)   | 0.860 (0.825–0.896)          |
| LR*       | 0.874 (0.853–0.894)   | 0.865 (0.833–0.897)          |
| RFC*      | 0.899 (0.881–0.917)   | 0.865 (0.835–0.894)          |

LR, logistic regression; SVM, support vector machine; RFC, random forest classifier; XGBoost, extreme gradient boosting; DNN, fully-connected deep neural network.

*indicates model developed with 21 variables.

### TABLE 3 | Scores for each model in the testing set.

| Models    | AUC (95% CI) | Specificity | Sensitivity | Precision | Accuracy |
|-----------|--------------|-------------|-------------|-----------|----------|
| LR        | 0.857 (0.814–0.900) | 0.912 | 0.620 | 0.761 | 0.821 |
| SVM       | 0.865 (0.823–0.907) | 0.912 | 0.602 | 0.756 | 0.816 |
| RFC       | 0.862 (0.820–0.904) | 0.883 | 0.657 | 0.717 | 0.813 |
| XGBoost   | 0.858 (0.815–0.901) | 0.895 | 0.630 | 0.731 | 0.813 |
| DNN       | 0.867 (0.827–0.908) | 0.891 | 0.556 | 0.811 | 0.821 |
| LR*       | 0.866 (0.825–0.907) | 0.921 | 0.593 | 0.780 | 0.821 |
| RFC*      | 0.874 (0.835–0.912) | 0.950 | 0.500 | 0.818 | 0.810 |

AUC, the area under the curve; LR, logistic regression; SVM, support vector machine; RFC, random forest classifier; XGBoost, extreme gradient boosting; DNN, fully-connected deep neural network.

*indicates model developed with 21 variables.

Boxes (23). Importantly, our model should be used together with, rather than instead of, clinical judgment. Combining machines plus physicians reliably enhances system performance. Hence, we should strongly consider the RFC model if accuracy is paramount.

As a popular ensemble method, RFC has been successfully applied in medical fields due to its ability to build predictive models with high certainty and little necessity of model optimization. In particular, the important advantages were shown in the RFC model compared with other methodologies, including the ability to handle highly non-linearly correlated data, robustness to noise, and tuning simplicity (24). In our research, some strategies to avoid overfitting were performed, and our results showed no signs of obvious overfitting in the RFC model. Additionally, to ensure an unbiased and robust performance, 5-fold cross-validation was iteratively used. The preceding characteristic features may make our model useful in real-world practice.

Several previous prognostic models have been developed to predict the clinical outcome after stroke, such as the HIAT score, the THRIVE score, and the NADE nomogram (3–5). The HIAT score identified three predictors of a 3-month unfavorable outcome in intra-arterial recanalization therapy, that is age > 75 years, NIHSS > 18, and baseline glucose level ≥ 150 mg/dL. It respectively, has an AUC value of 0.69 and 0.73 in two cohorts (3). The THRIVE score identified age, NIHSS, hypertension, diabetes mellitus, and atrial fibrillation...
are independently associated with a 3-month poor outcome (4). It was well-validated with a large sample size from the Virtual International Stroke Trials Archive and had an AUC of 0.75 (25). The NADE nomogram was developed to predict 6-month unfavorable outcome after AIS (5). NIHSS at admission, age, previous diabetes mellitus, and creatinine were found to be significant predictors. The AUC value of the NADE nomogram was 0.791. In our study, only five variables—age, NIHSS on admission, premorbid mRS, FBG, and creatinine—were included into our models. NIHSS and premorbid mRS indicated that stroke severity and degree of dependence in the daily activities influenced the stroke outcome. Blood glucose has been proven to be not only associated with stroke outcome but also a risk factor of symptomatic intracerebral hemorrhage after thrombolysis therapy (26). Creatinine is an indicator of renal function. However, the relationship between renal function and stroke outcomes is controversial (27, 28). Indeed, after excluding some less important and even misleading variables for stroke outcome, ML models based on 5 and 21 variables have achieved similar performance. This illustrates that the five variables we selected contained almost all useful information in the original data. In addition, variable importance derived from the RFC and LR with 21 variables also provides insight for the importance of individual variables in prediction performance.

There are some limitations in our study. First, our population was from a single hospital. The generalizability of the predictive models needs to be tested in patients treated at other institutions and by other surgeons. Second, there were some cases that were lost to follow-up. Especially, of total 1,213 cases excluded from this study for loss of 6-month follow-up, 944 cases (78%) were lost between May 2017 and March 2018, accounting for 85% of the AIS patients during that period. It is unclear whether we have overestimated or underestimated the unfavorable outcome after AIS. But we believe this centralized loss of data may have less impact on the results. Finally, data of known neurobiological predictors of 3-month outcome such as infarct size (29) were not available in our study. Future prospective studies will have to assess whether incorporating novel predictors may improve the accuracy of predictive model.

**CONCLUSIONS**

To sum up, the comparison with the previous models demonstrated that it is feasible to apply the RFC model to stroke patient management, which achieves optimal performance compared with the HIAT score, THRIVE score, and NADE nomogram. Moreover, the RFC model is easy to use and robust. These advanced characteristics may contribute to reliable and practical applications in clinical practice.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study are available on request to the corresponding author.

**ETHICS STATEMENT**

Approval from the ethics committee of Nanjing First Hospital was obtained.

**AUTHOR CONTRIBUTIONS**

XL and JZo concepted, designed, and supervised the study. JZh, YL, FW, XZ, JY, and YZ acquired the data. XL and ZZ analyzed and interpreted the data, provided statistical analysis, had full access to all of the data in the study, and are responsible for the integrity of the data and the accuracy of the data analysis. XL, XP, MW, CS, ZZ, and SW drafted the manuscript. JZo and CJ critically revised the manuscript for important intellectual content.
All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by National Natural Science Foundation of China grant 81673511, Jiangsu Key Research and Development Plan grant BE2017613, Jiangsu Six Talent Peaks Project grant WSN-151, and Nanjing Medical Science and Technique Development Foundation grant QRX17020.

**REFERENCES**

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American heart association. *Circulation*. (2018) 137:e67. doi: 10.1161/CIR.0000000000000573

2. Raji et al. Gothe H, Borba HH, Sroczynski G, Vujicic J, Toell T, et al. Economic burden of stroke: a systematic review on post-stroke care. *Eur J Health Econ*. (2019) 20:107–34. doi: 10.1007/s10198-018-0984-0

3. Halliwell B, Barreto AD, Morales MM, MartinSchild SB, Abraham AT, et al. Identifying patients at high risk for poor outcome after intra-arterial therapy for acute ischemic stroke. *Stroke*. (2009) 40:1780–5. doi: 10.1161/STROKEAHA.108.535146

4. Flint AC, Cullen SP, Faigeles BS, Rao, VA. Predicting long-term outcome after endovascular stroke treatment: the total health risks in vascular events score. *Am J Neuroradiol*. (2010) 31:1192–6. doi: 10.3174/ajnr.A2050

5. Sun C, Li X, Song B, Chen X, Nyame L, Liu Y, et al. A NADE nomogram to predict the probability of 6-month unfavorable outcome in Chinese patients with ischemic stroke. *BMC Neurol*. (2019) 19:274. doi: 10.1186/s12883-019-1464-6

6. Tsai CF, Brenda T, Sudlow C. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. *Neurology*. (2013) 81:264–72. doi: 10.1212/01.wnl.0000418296.dde3

7. Qian F, Fonarow GC, Smith EE, Xian Y, Pan W, Hannon EL, et al. Racial and ethnic differences in outcomes in older patients with acute ischemic stroke. *Circ Cardiovasc Qual Outcomes*. (2013) 6:284–92. doi: 10.1161/CIRCOUTCOMES.113.003211

8. Kumar N, Khera R, Pandey A, Garg N. Racial differences in outcomes after acute ischemic stroke hospitalization in the united states. *J Stroke Cerebrovasc Dis*. (2016) 25:1970–7. doi: 10.1016/j.jsct.2016.03.049

9. Xian Y, Holloway RG, Noyes K, Shah MN, Friedman B. Racial differences in mortality among patients with acute ischemic stroke: an observational study. *Ann Intern Med*. (2011) 54:152–9. doi: 10.7326/0003-4819-154-3-201102010-00004

10. Kamal H, Lopez V, Sherb SA. Machine learning in acute ischemic stroke neuroimaging. *Front Neurol*. (2018) 9:945. doi: 10.3389/fneur.2018.00945

11. Goldstein BA, Navar AM, Carter RE. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. *Eur Heart J*. (2017) 38:1805–14. doi: 10.1093/eurheartj/hex302

12. Meyer A, Zverinski D, Pfahringer B, Kempfert J, Kuehne T, Sundermann SH, et al. Machine learning for real-time prediction of complications in critical care: a retrospective study. *Lancet Respir Med*. (2018) 6:905–14. doi: 10.1016/S2213-2600(18)30300-X

13. Goto T, Jo T, Matsui H, Fushimi K, Hayashi H, Yasunaga H. Machine learning-based prediction models for 30-day readmission after hospitalization for chronic obstructive pulmonary disease. *COPD*. (2019) 16:338–43. doi: 10.1080/15412255.2019.1688278

14. Deo RC. Machine learning in medicine. *Circulation*. (2015) 132:1920–30. doi: 10.1161/CIRCULATIONAHA.115.018593

15. Wolpert DH. *The Supervised Learning No-Free-Lunch Theorems. Soft Computing and Industry*. London: Springer (2002). p. 25–42. doi: 10.1007/978-1-4471-0123-9_3

16. Montazeri M, Montazeri A, Montazeri M, Beigzadeh A. Machine learning models in breast cancer survival prediction. *Technol Health Care*. (2016) 24:31–42. doi: 10.3233/THC-151071

17. Garg R Prabhakaran S, Holl JL, Luo Y, Faigle R, Kording K, et al. Improving the accuracy of scores to predict gastrostomy after intracerebral hemorrhage with machine learning. *J Stroke Cerebrovasc Dis*. (2018) 27:3570–4. doi: 10.1016/j.jstrokecerevasdis.2018.08.026

18. Cherupke MM, Yuen TC, Winslow C, Meltzer DO, Kattan MW, Edelson DP. Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. *Crit Care Med*. (2016) 44:368–74. doi: 10.1097/CCM.0000000000001571

19. Nishi H, Oishi N, Ishii A, Ono I, Ogura T, Sunohara T, et al. Predicting clinical outcomes of large vessel occlusion before mechanical thrombectomy using machine learning. *Stroke*. (2019) 50:2379–88. doi: 10.1161/STROKEAHA.119.025411

20. Abedi V, Goyal N, Taiygouls G, Hosseinichimeh N, Montecillas R, Bassaganya-Riera J, et al. Novel screening tool for stroke using artificial neural network. *Stroke*. (2017) 48:1678–81. doi: 10.1161/STROKEAHA.117.017033

21. Liggins JTP, Yoo AJ, Mishra NK, Wheeler HM, Straka M, Leslie-Mazwi TM, et al. A score based on age and DWI volume predicts poor outcome following endovascular treatment for acute ischemic stroke. *Int J Stroke*. (2015) 10:705–9. doi: 10.1111/ijs.12207

22. Ntios G, Fouazi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRA score. *Neurology*. (2012) 78:1916–22. doi: 10.1212/WNL.0b013e31825e221

23. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. *Nat. Mach. Intell.* (2019) 1:206–15. doi: 10.1038/s42256-019-0048-x

24. Caruana R, Niculescu-Mizil, A. An empirical comparison of supervised learning algorithms. In: *Proceedings of the 23rd International Conference on Machine Learning* (Pittsburgh, PA: ACM) (2006). p. 161–8. doi: 10.1145/1143844.1143865

25. Flint AC, Faigeles BS, Cullen SP, Kamed H, Rao VA, Gupta R, et al. THRIVE score predicts ischemic stroke outcomes and thrombolytic hemorrhage risk in VISTA. *Stroke*. (2013) 44:3365–9. doi: 10.1161/STROKEAHA.113.002794

26. Rocco A, Heuschmann PU, Schellinger PD, Köhrmann M, Diedler J, Sykora M, et al. Glycosylated hemoglobin A1 predicts risk for symptomatic hemorrhage after thrombolysis for acute stroke. *Stroke*. (2014) 45:2313–4. doi: 10.1161/STROKEAHA.111.675918

27. Nugroho AW, Arima H, Miyazawa I, Fujii T, Miyamatsu N, Sugimoto Y, et al. Introduction of direct oral anticoagulant within 7 days of stroke for chronic obstructive pulmonary disease. *Am J Neuroradiol*. (2018) 39:2214–8. doi: 10.3174/ajnr.A5921

28. Yang J, Arima H, Zhou J, Zhao Y, Li Q, Wu G, et al. Glycosylated hemoglobin A1 predicts risk for symptomatic hemorrhage after thrombolysis for acute stroke. *Stroke*. (2013) 44:2313–4. doi: 10.1161/STROKEAHA.111.675918

29. Cappellari M, Turcato G, Forlivesi S, Micheletti N, Tomelleri G, Bonetti B, et al. Introduction of direct oral anticoagulant within 7 days of stroke

**ACKNOWLEDGMENTS**

We gratefully acknowledge all the patients who participated in this study and to those who have provided their medical care.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.539509/full#supplementary-material
onset: a nomogram to predict the probability of 3-month modified Rankin scale score. 2. J Thromb Thrombolysis. (2018) 46:292–8. doi: 10.1007/s11239-018-1700-8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.